ERCC2 and colorectal carcinoma: ADCY8, BLM, BRCA2, ERCC2, REV3L, RIF1, SEC23B, SMARCA4 and STK11IP were highlighted for harboring a significant enrichment in CRC cases for more than 50% of the potentially disrupting variants (Table S3).